<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181126</url>
  </required_header>
  <id_info>
    <org_study_id>M16-106</org_study_id>
    <nct_id>NCT03181126</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma</brief_title>
  <official_title>A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary
      efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric
      participants with relapsed/refractory acute lymphoblastic leukemia (ALL) or
      relapsed/refractory lymphoblastic lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">June 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Venetoclax + Navitoclax</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of venetoclax + navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Venetoclax + Navitoclax</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) of venetoclax + navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Venetoclax + Navitoclax</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Time to Cmax (Tmax) of Venetoclax + Navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of Venetoclax + Navitoclax</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Apparent oral clearance (CL/F) of venetoclax + navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicities (DLT)</measure>
    <time_frame>Up to approximately 35 days after initial dose of study drug</time_frame>
    <description>A DLT is any Grade 3 or higher non-hematologic adverse event (AE) with exceptions outlined in the protocol. AEs and toxicities that occur beyond the DLT assessment period will also be evaluated by the investigator and AbbVie and may be considered as dose-limiting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 9 months after the last subject has enrolled into the study</time_frame>
    <description>PFS is defined as the number of days from the date of enrollment to the date of earliest disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR) rate</measure>
    <time_frame>Up to 9 months after the last subject has enrolled into the study</time_frame>
    <description>PR defined as no peripheral blasts or peripheral blood absolute blast count decreased by ≥ 50% from baseline, bone marrow with 5 - 25% blasts and at least a 50% decrease in bone marrow blast percent from baseline, no evidence of extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant who Proceed to Stem Cell Transplantation</measure>
    <time_frame>Up to 9 months after the last subject has enrolled into the study</time_frame>
    <description>Determine the number of participants who proceed to stem cell transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 9 months after the last subject has enrolled into the study</time_frame>
    <description>OS is defined as the number of days from the date of enrollment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 9 months after the last subject has enrolled into the study</time_frame>
    <description>The proportion of subjects with objective response rate (complete response [CR] + CR incomplete recovery [CRi] + CR without platelet recovery [CRp]) for ALL subjects and (CR+PR) for LL subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>Up to 9 months after the last subject has enrolled into the study</time_frame>
    <description>CR defined as hematologic recovery (absolute neutrophil count [ANC] greater than or equal to 500/μL; platelet counts greater than or equal to 75,000/μL), evidence of trilineage hematopoiesis in the bone marrow and less than 5% blasts in the bone marrow, absence of circulating blasts, and no evidence of extramedullary disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Venetoclax + Navitoclax + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase [or any other forms of asparaginase], vincristine, dexamethasone) and tyrosine kinase inhibitor [TKI, if applicable]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navitoclax</intervention_name>
    <description>tablet</description>
    <arm_group_label>Venetoclax + Navitoclax + Chemotherapy</arm_group_label>
    <other_name>ABT-263</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)</description>
    <arm_group_label>Venetoclax + Navitoclax + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet</description>
    <arm_group_label>Venetoclax + Navitoclax + Chemotherapy</arm_group_label>
    <other_name>ABT-199 GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have relapsed or refractory acute lymphoblastic leukemia (ALL) or relapsed or
             refractory lymphoblastic lymphoma (LL). Refractory is defined as persistent disease
             after at least 2 courses of chemotherapy.

               -  Participants with ALL with Philadelphia chromosome or with an ABL class
                  targetable fusion are eligible.

               -  Participants with LL must have radiographic evidence of disease

          -  Must weigh greater than or equal to 20 kg.

          -  Must be able to swallow pills.

          -  Must have adequate hepatic and kidney function.

          -  Must have adequate performance status:

               -  Participants less than or equal to 16 years of age: Lansky greater than or equal
                  to 50

               -  Participants greater than 16 years of age: Karnofsky greater than or equal to 50
                  or Eastern Cooperative Oncology Group (ECOG) less than 3.

        Exclusion Criteria:

          -  Participant has overt central nervous system (CNS) disease (CNS 3 status)

          -  Participants who are less than 100 days post-transplant, or greater than 100 days
             post-transplant with active graft versus host disease (GVHD), or are still continuing
             post-transplant immunosuppressant therapy within 7 days prior to the first dose of
             study drug.

          -  Participants who have received any of the following prior to the first dose of study
             drug:

               -  Inotuzumab within 30 days and must have ALT, AST and bilirubin &lt; ULN.

               -  A biologic agent (i.e., monoclonal antibodies) for anti-neoplastic intent within
                  30 days

               -  CAR-T infusion or other cellular therapy within 30 days

               -  any anti-cancer therapy including blinatumomab, chemotherapy, radiation therapy
                  targeted small molecule agents or investigational agents within 14 days, or 5
                  half-lives, whichever is shorter

               -  Steroid therapy for anti-neoplastic intent within 5 days

               -  Hydroxyurea that is ongoing (hydroxyurea is permitted up to the first dose)

               -  A strong or moderate CYP3A inhibitor or inducer within 7 days

               -  Aspirin within 7 days, or 5 half-lives, whichever is longer

               -  An antiplatelet/anticoagulant drug or a herbal supplement that affects platelet
                  function within 7 days, or 5 half-lives, whichever is longer

          -  Participants with malabsorption syndrome or any other condition that precludes enteral
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LPCH Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ NC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514-4220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Childrens Res Hosp</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-7208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madiso</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Victorian Comprehensive Cancer</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed of Refractory Acute Lymphoblastic Leukemia</keyword>
  <keyword>Cancer</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Navitoclax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Navitoclax</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

